August 13, 2019 | Daily JAM, NKTR, Stock Alerts, Volatility |
What we know about Nektar Therapeutics (NKTR) is pretty clear. On Thursday of last week, August 8, trading in shares of Nektar were halted on news from the company had manufacturing problems that resulted in some patients enrolled in the clinical trials for the...
July 9, 2019 | Daily JAM, SGMO, Stock Alerts, Volatility |
On July 5 Sangamo Therapeutics (SGMO) and partner Pfizer (PFE) announced update results of a Phase 1/2 study of Sangamo's SB-525 gene therapy for severe hemophilia A. The companies also announced that the U.S. Food & Drug Administration had granted regenerative...
July 5, 2019 | Daily JAM, MRK, PFE |
It's good to know that in this sometimes confusing and volatile market some things remain constant. A high-profile figure says something about the need to lower drug prices and drug stocks tumble. Whether the "something" is likely to result in action or not. Today it...
June 18, 2019 | CTVA, Daily JAM, Special Reports, Volatility, You Might Have Missed |
This isn't  time for investing as usual. As whacky as the first half of 2019 has been--the Federal Reserve embraces interest rate cuts, the U.S. and China descend further into a trade war, the U.S. economy turns in better than 3% growth but fears for a slowdown in...
June 17, 2019 | Daily JAM, NKTR, PE, Stock Alerts |
Again. I'm adding the January 17, 2020 Call Options with a strike at $35 on Nektar Theraeutics (NKTR) to my Volatility Portfolio on JubakAM.com and JugglingWithKnives.com. (Ticker on these options is NKTR200117C00035000.) The underlying shares closed at $33.70, up...
May 24, 2019 | Daily JAM, INCY, Stock Alerts |
Jubak Picks and Volatility Portfolio member Incyte (INCY) closed up 1.55% today to $81.75 on news that the U.S. Food and Drug Administration had approved the company's Jakafi for treatment for acute Graft versus Host disease (GvHD), an inflammatory response by the...
April 10, 2019 | Daily JAM, INCY, Volatility, You Might Have Missed |
There's a good chance that Incyte (INCY) will miss Wall Street earnings and revenue projections when it reports first quarter results on April 30. That's because Incyte is a biotech adolescent. Think awkward. The company is old enough to have substantial revenue from...
April 4, 2019 | Daily JAM, NKTR, Stock Alerts |
Nektar Therapeutics (NKTR) won't miss Wall Street earnings projections when it reports its first quarter financial results on May 9--because the company won't report any earnings. The consensus projection now has the company reporting a loss of 76 cents a share on...
April 2, 2019 | Daily JAM, SGMO, Stock Alerts |
Two big pieces of positive news popped shares of Sangamo Therapeutics (SGMO) today by 28.96% at the close. First, Sangamo announced interim data from its Hemophilia A program with Pfizer (PFE). The SB-525 gene therapy Phase 1/2 study in eight patients showed...
January 27, 2019 | Daily JAM, IONS, Stock Alerts, Volatility |
To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the...
January 13, 2019 | Daily JAM, Stock Alerts |
Back on November 27, I launched a "Special Report: My 10 small company stock picks for the January Effect." What with tremendous volatility in the market, the beginning of a bear market for some sectors, and the failure of the January Effect to arrive on schedule in...
January 8, 2019 | Daily JAM, INCY, IONS, NKTR |
Last week the biotech sector seemed in freewill. Bristol Myers Squibb (BMY) had made a deal to buy Celgene (CELG) at a whopping 54% premium to Wednesday's close and the sector dropped on the news. The prevailing theory was that the deal removed one hungry big drug...